Business
GenSight Biologics Reports Cash Position as of June 30, 2025
PARIS, July 08, 2025--Regulatory News: GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2025.
About this update from Gensight Biologics Sa
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":204,"url":"https://media.zenfs.com/en/business-wire.com/4d04e5c2ac0032b525a4e4623e097190"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7F4bGdoVp_lGfhr5VbHSfw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQwODtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/4d04e5c2ac0032b525a4e4623e097190","width":480,"height":204}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Operations funded until early October 2025 as a result of disciplined spending controls","length":87,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Agreement with the ANSM to consider opening the Named Early Access Program (AAC) for LUMEVOQ® in France in Q4 2025","length":114,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Significant milestone in new manufacturing partnership with Catalent","length":68,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Successful completion of private placement financing amounting to close to EUR 4 million","length":88,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":357,"olType":false},{"type":"text","content":"PARIS, July 08, 2025--(BUSINESS WIRE)--Regulatory News:","length":55,"tagName":"p"},{"type":"text","content":"GenSight Biologics ("GenSight Biologics" or the "Company") (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its cash position as of June 30, 2025.","length":354,"tagName":"p"},{"type":"text","content":""The second quarter of 2025 marked a period of significant operational progress for GenSight Biologics. We successfully completed the technology transfer of LUMEVOQ's upstream manufacturing process to our new partner Catalent, secured the ANSM's agreement to consider opening the AAC program in France, and closed our private placement financing in July," commented Jan Eryk Umiastowski, CFO of GenSight Biologics. "We continue to actively pursue non-dilutive financing options to support our critical value-driving activities. With the AAC program launch planne...